Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 664

1.

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy.

Del Re M, Crucitta S, Gianfilippo G, Passaro A, Petrini I, Restante G, Michelucci A, Fogli S, de Marinis F, Porta C, Chella A, Danesi R.

Int J Mol Sci. 2019 Aug 14;20(16). pii: E3951. doi: 10.3390/ijms20163951. Review.

2.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC.

Eur Urol Oncol. 2019 Apr 4. pii: S2588-9311(19)30041-0. doi: 10.1016/j.euo.2019.03.007. [Epub ahead of print]

PMID:
31411994
3.
4.

Toward a genome-based treatment landscape for renal cell carcinoma.

Massari F, Di Nunno V, Santoni M, Gatto L, Caserta C, Morelli F, Zafarana E, Carrozza F, Mosca A, Mollica V, Iacovelli R, Sabbatini R, Porta C, Bracarda S.

Crit Rev Oncol Hematol. 2019 Aug 2;142:141-152. doi: 10.1016/j.critrevonc.2019.07.020. [Epub ahead of print] Review.

PMID:
31401421
5.

Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.

Vitale MG, Baldessari C, Milella M, Buti S, Militello AM, Di Girolamo S, Fornarini G, Perri G, Basso U, Maruzzo M, Porta C, Cosmai L, Pipitone S, Cerma K, Cascinu S, Sabbatini R.

Clin Genitourin Cancer. 2019 Jul 8. pii: S1558-7673(18)30794-8. doi: 10.1016/j.clgc.2019.06.009. [Epub ahead of print] No abstract available.

PMID:
31375351
6.

First- and Second-Hand Experiences of Enacted Stigma Among LGBTQ Youth.

Gower AL, Valdez CAB, Watson RJ, Eisenberg ME, Mehus CJ, Saewyc EM, Corliss HL, Sullivan R, Porta CM.

J Sch Nurs. 2019 Jul 23:1059840519863094. doi: 10.1177/1059840519863094. [Epub ahead of print]

PMID:
31337243
7.

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C.

Eur Urol Oncol. 2019 Jul 19. pii: S2588-9311(19)30099-9. doi: 10.1016/j.euo.2019.06.018. [Epub ahead of print]

PMID:
31331862
8.

Effects of Creatine Treatment on Jejunal Phenotypes in a Rat Model of Acidosis.

Sironi C, Bodega F, Zocchi L, Porta C.

Antioxidants (Basel). 2019 Jul 17;8(7). pii: E225. doi: 10.3390/antiox8070225.

9.

Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM).

Vitale MG, Bracarda S, Cosmai L, Crocetti E, Di Lorenzo G, Lapini A, Mandressi A, Martorana G, Masini C, Montironi R, Ortega C, Passalacqua R, Porta C, Procopio G, Sepe P, Romano L, Pappagallo GL, Conti G, Guida M, Martignoni G, Nolè F, Pignata S, Gori S, Cartenì G.

Tumori. 2019 Jul;105(4_suppl):3-12. doi: 10.1177/0300891619853392.

PMID:
31264522
10.

Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell Carcinoma.

Nesiu A, Cimpean AM, Ceausu RA, Adile A, Ioiart I, Porta C, Mazzanti M, Camerota TC, Raica M.

Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):299-307. doi: 10.21873/cgp.20135.

11.

"It makes such a difference": An examination of how LGBTQ youth talk about personal gender pronouns.

Brown C, Frohard-Dourlent H, Wood BA, Saewyc E, Eisenberg ME, Porta CM.

J Am Assoc Nurse Pract. 2019 Jun 19. doi: 10.1097/JXX.0000000000000217. [Epub ahead of print]

PMID:
31232865
12.

Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper.

Silvestris N, Argentiero A, Cosmai L, Porta C, Gesualdo L, Brunori G, Brunetti O, Rampino T, Secondino S, Rizzo G, Pedrazzoli P.

Crit Rev Oncol Hematol. 2019 Aug;140:39-51. doi: 10.1016/j.critrevonc.2019.05.016. Epub 2019 May 31. Review.

13.

Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.

Consonni FM, Porta C, Marino A, Pandolfo C, Mola S, Bleve A, Sica A.

Front Immunol. 2019 May 3;10:949. doi: 10.3389/fimmu.2019.00949. eCollection 2019. Review.

14.

Molecular mechanisms of heterogeneous oligomerization of huntingtin proteins.

Bonfanti S, Lionetti MC, Fumagalli MR, Chirasani VR, Tiana G, Dokholyan NV, Zapperi S, La Porta CAM.

Sci Rep. 2019 May 20;9(1):7615. doi: 10.1038/s41598-019-44151-0.

15.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
16.

AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.

Del Re M, Crucitta S, Sbrana A, Rofi E, Paolieri F, Gianfilippo G, Galli L, Falcone A, Morganti R, Porta C, Efstathiou E, van Schaik R, Jenster G, Danesi R.

BJU Int. 2019 May 4. doi: 10.1111/bju.14792. [Epub ahead of print]

PMID:
31055861
17.

Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel.

Quaquarini E, D'Ambrosio D, Sottotetti F, Gallivanone F, Hodolic M, Baiardi P, Palumbo R, Vellani C, Canevari C, Bernardo A, Castiglioni I, Porta C, Trifirò G.

Contrast Media Mol Imaging. 2019 Mar 26;2019:4325946. doi: 10.1155/2019/4325946. eCollection 2019.

18.

Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?

Porta C, Cosmai L, Rizzo M, Melazzini M.

Ann Transl Med. 2019 Mar;7(Suppl 1):S15. doi: 10.21037/atm.2019.01.51. No abstract available.

19.

Immune-based combination therapy for metastatic kidney cancer.

Porta C, Rizzo M.

Nat Rev Nephrol. 2019 Jun;15(6):324-325. doi: 10.1038/s41581-019-0149-0. No abstract available.

PMID:
30992548
20.

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group.

J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z.

21.

Perceptions of Sexual Orientation and Gender Identity Minority Adolescents About Labels.

Porta CM, Gower AL, Brown C, Wood B, Eisenberg ME.

West J Nurs Res. 2019 Apr 3:193945919838618. doi: 10.1177/0193945919838618. [Epub ahead of print]

PMID:
30943875
22.

Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.

Nunno VD, Mollica V, Gatto L, Santoni M, Cosmai L, Porta C, Massari F.

Immunotherapy. 2019 May;11(7):631-643. doi: 10.2217/imt-2018-0175.

PMID:
30943858
23.

The effect of a treatment delay on outcome in metastatic renal cell carcinoma.

Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G.

Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29.

PMID:
30935843
24.

Combination pharmacotherapy for tackling descending controls and central sensitization.

Treede RD, Schuh-Hofer S, Magerl W, La Porta C, Tappe-Theodor A.

Eur J Pain. 2019 Jul;23(6):1049-1050. doi: 10.1002/ejp.1396. Epub 2019 Apr 30. No abstract available.

PMID:
30929296
25.

The adjuvant treatment of kidney cancer: a multidisciplinary outlook.

Porta C, Cosmai L, Leibovich BC, Powles T, Gallieni M, Bex A.

Nat Rev Nephrol. 2019 Jul;15(7):423-433. doi: 10.1038/s41581-019-0131-x. Review.

PMID:
30914797
26.

Relationships Between Adolescent Stress, Depressive Symptoms, and Sexual Risk Behavior in Young Adulthood: A Structural Equation Modeling Analysis.

Ghobadzadeh M, McMorris BJ, Sieving RE, Porta CM, Brady SS.

J Pediatr Health Care. 2019 Jul - Aug;33(4):394-403. doi: 10.1016/j.pedhc.2018.11.006. Epub 2019 Mar 19.

PMID:
30898497
27.

Sulforaphane Cannot Protect Human Fibroblasts From Repeated, Short and Sublethal Treatments with Hydrogen Peroxide.

Lionetti MC, Mutti F, Soldati E, Fumagalli MR, Coccé V, Colombo G, Astori E, Miani A, Milzani A, Dalle-Donne I, Ciusani E, Costantini G, La Porta CAM.

Int J Environ Res Public Health. 2019 Feb 23;16(4). pii: E657. doi: 10.3390/ijerph16040657.

28.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee.

Ann Oncol. 2019 May 1;30(5):706-720. doi: 10.1093/annonc/mdz056. No abstract available.

PMID:
30788497
29.

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ.

Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28.

30.

Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient.

Porta C, Broglia C, Negri F.

Hepatology. 2019 Jul;70(1):429-430. doi: 10.1002/hep.30521. Epub 2019 Mar 13. No abstract available.

PMID:
30681728
31.

Targeting angiogenesis in metastatic renal cell carcinoma.

Canino C, Perrone L, Bosco E, Saltalamacchia G, Mosca A, Rizzo M, Porta C.

Expert Rev Anticancer Ther. 2019 Mar;19(3):245-257. doi: 10.1080/14737140.2019.1574574. Epub 2019 Feb 6.

PMID:
30678509
32.

Effect of Cyclic Stretch on Vascular Endothelial Cells and Abdominal Aortic Aneurysm (AAA): Role in the Inflammatory Response.

Ramella M, Bertozzi G, Fusaro L, Talmon M, Manfredi M, Catoria MC, Casella F, Porta CM, Boldorini R, Fresu LG, Marengo E, Boccafoschi F.

Int J Mol Sci. 2019 Jan 12;20(2). pii: E287. doi: 10.3390/ijms20020287.

33.

Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells.

Maliszewska-Olejniczak K, Brodaczewska KK, Bielecka ZF, Solarek W, Kornakiewicz A, Szczylik C, Porta C, Czarnecka AM.

Cytotechnology. 2019 Feb;71(1):149-163. doi: 10.1007/s10616-018-0273-x. Epub 2018 Dec 31.

34.

Fibrin sealant repair of a double-necked femoral pseudoaneurysm.

Flumignan R, Guedes Neto H, Araujo S, Giulio YD, Porta C, Amorim J, Nakano L.

Rev Assoc Med Bras (1992). 2018 Dec;64(12):1069-1072. doi: 10.1590/1806-9282.64.12.1069.

35.

Luminescent conjugates between dinuclear rhenium complexes and 17α-ethynylestradiol: synthesis, photophysical characterization, and cell imaging.

Proverbio M, Quartapelle Procopio E, Panigati M, Mercurio S, Pennati R, Ascagni M, Leone R, La Porta C, Sugni M.

Org Biomol Chem. 2019 Jan 16;17(3):509-518. doi: 10.1039/c8ob02472c.

PMID:
30569048
36.

Smoking behaviours among heterosexual and sexual minority youth? Findings from 15 years of provincially representative data.

Fish JN, Watson RJ, Gahagan J, Porta CM, Beaulieu-Prévost D, Russell ST.

Drug Alcohol Rev. 2019 Jan;38(1):101-110. doi: 10.1111/dar.12880. Epub 2018 Nov 26.

PMID:
30478862
37.

The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review.

Poletto V, Rosti V, Biggiogera M, Guerra G, Moccia F, Porta C.

Crit Rev Oncol Hematol. 2018 Dec;132:89-99. doi: 10.1016/j.critrevonc.2018.09.005. Epub 2018 Sep 18. Review.

PMID:
30447930
38.

Author Correction: Probing spermiogenesis: a digital strategy for mouse acrosome classification.

Taloni A, Font-Clos F, Guidetti L, Milan S, Ascagni M, Vasco C, Pasini ME, Gioria MR, Ciusani E, Zapperi S, La Porta CAM.

Sci Rep. 2018 Nov 14;8(1):17060. doi: 10.1038/s41598-018-35541-x.

39.

Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review.

Bracarda S, Porta C, Sabbatini R, Rivoltini L.

Crit Rev Oncol Hematol. 2019 Jul;139:149-157. doi: 10.1016/j.critrevonc.2018.07.009. Epub 2018 Aug 1. Review.

PMID:
30424938
40.

Relevance of inflammation and matrix remodeling in abdominal aortic aneurysm (AAA) and popliteal artery aneurysm (PAA) progression.

Ramella M, Bernardi P, Fusaro L, Manfredi M, Casella F, Porta CM, Nicolai L, Galeazzi E, Boldorini R, Settembrini AM, Settembrini P, Marengo E, Cannas M, Boccafoschi F.

Am J Transl Res. 2018 Oct 15;10(10):3265-3275. eCollection 2018.

41.

Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison.

Porta C, Szczylik C, Casciano R, Fu S, Amzal B, Lister J, Karcher H, Meng J, Neumann M, Dinet J.

Crit Rev Oncol Hematol. 2019 Jul;139:143-148. doi: 10.1016/j.critrevonc.2018.10.004. Epub 2018 Oct 24. Review.

42.

Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines.

Frascà GM, Brigante F, Volpe A, Cosmai L, Gallieni M, Porta C.

J Nephrol. 2019 Feb;32(1):57-64. doi: 10.1007/s40620-018-0542-y. Epub 2018 Oct 16. Review.

43.

Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.

Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C.

Target Oncol. 2018 Dec;13(6):705-714. doi: 10.1007/s11523-018-0601-2. Review.

PMID:
30324488
44.

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC.

Cancer. 2018 Sep 15;124(18):3677-3683. doi: 10.1002/cncr.31595. Epub 2018 Oct 11.

PMID:
30307610
45.

Endovascular repair of popliteal artery aneurysms: an Italian multicenter study.

Guzzardi G, Natrella M, Del Sette B, Petullà M, Fanelli G, Porta C, Carriero A, Laganà D.

Radiol Med. 2019 Jan;124(1):79-85. doi: 10.1007/s11547-018-0941-0. Epub 2018 Sep 19.

PMID:
30232731
46.

The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.

Calvo E, Porta C, Grünwald V, Escudier B.

Oncologist. 2019 Mar;24(3):338-348. doi: 10.1634/theoncologist.2018-0267. Epub 2018 Aug 29. Review.

PMID:
30158285
47.

Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.

Mantovani S, Oliviero B, Lombardi A, Varchetta S, Mele D, Sangiovanni A, Rossi G, Donadon M, Torzilli G, Soldani C, Porta C, Pedrazzoli P, Chiellino S, Santambrogio R, Opocher E, Maestri M, Bernuzzi S, Rossello A, Clément S, De Vito C, Rubbia-Brandt L, Negro F, Mondelli MU.

Hepatology. 2019 Mar;69(3):1165-1179. doi: 10.1002/hep.30235. Epub 2019 Feb 14.

PMID:
30153337
48.

Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis.

Iacovelli R, Ciccarese C, Bria E, Bimbatti D, Fantinel E, Mosillo C, Bisogno I, Brunelli M, Tortora G, Porta C.

Cancer Treat Rev. 2018 Nov;70:112-117. doi: 10.1016/j.ctrv.2018.08.007. Epub 2018 Aug 20. Review.

PMID:
30145397
49.

Inflammatory and neuropathic pain conditions do not primarily evoke anxiety-like behaviours in C57BL/6 mice.

Pitzer C, La Porta C, Treede RD, Tappe-Theodor A.

Eur J Pain. 2019 Feb;23(2):285-306. doi: 10.1002/ejp.1303. Epub 2018 Sep 3.

PMID:
30098102
50.

The role of tivozanib in advanced renal cell carcinoma therapy.

Escudier B, Porta C, Eisen T, Belsey J, Gibson D, Morgan J, Motzer R.

Expert Rev Anticancer Ther. 2018 Nov;18(11):1113-1124. doi: 10.1080/14737140.2018.1508348. Epub 2018 Aug 21. Review.

PMID:
30084668

Supplemental Content

Support Center